# GEHC Completion Checker

Last updated: 2026-07-04 | pipeline: lean-6module-v1.1 | as_of: 2026-07-04

---

## Standard File Set Checklist

| File | Status | Notes |
|---|---|---|
| raw/10k_fy2025_extract.md | DONE | Secondary-sourced (SEC 403, fallback to stocktitan.net mirror) |
| raw/q1_2026_earnings_extract.md | DONE | Secondary-sourced (SEC 403, fallback) |
| facts.md | DONE | EVIDENCE (55 numbered items) / INTERPRETATION (9 items) / SENTIMENT (3 items) / OPEN (9 items) |
| claim_ledger.csv | DONE | 73 claims, each with source_id, tier, as_of date |
| source_register.md | DONE | 22 sources registered, ≥6 minimum requirement met (A1/A2 primary or proxy: 8; B1/B2 secondary: 13; C1: 1) |
| business_model.md | DONE | Four segments (Imaging/AVS/PCS/PDx) + segment reorg forward-flag |
| value_chain_map.md | DONE | Upstream/GEHC/downstream + profit pool table + bottleneck candidates |
| moat_map.md | DONE | 4 moat sources scored + weaknesses + scorecard table |
| operator_underwriting.md | DONE | CEO Peter Arduini graded 3/5 with explicit rationale |
| bottleneck_map.md | DONE | Installed-base + PDx cold-chain + China VBP-as-inverted-bottleneck (career-relevant module) |
| financials/financial_quality.md | DONE | Margin trend, FCF quality, leverage trend, one-off registry, verdict |
| inversion_map.md | DONE | 4 kill paths with evidence-for/against + what-would-not-kill-thesis section |
| valuation.md | DONE | Peer multiple analysis + 3-scenario IRR + buy-below table |
| model/scenario_model.csv | DONE | Bear/base/bull at 3yr/5yr with full methodology notes |
| ic_panel.md | DONE | 5-soul initial verdicts + 1 critique round + chair synthesis + kill criteria — unanimous WATCH, no fabricated quotes (only verifiable general public stances referenced) |
| decision_card.json | DONE | Full schema matching GEV/MSFT exemplar structure |
| decision_card.md | DONE | Human-readable summary with career note section |
| brief-v1.html | DONE | GEHC 决策简报 as_of 2026-07-04, MSFT template adapted, renders correctly (confirmed via Launch preview) |
| audit.md | DONE | Stale-claim check, internal consistency (13 checks, all PASS), one-off registry, source coverage, robustness-rule compliance |
| completion_checker.md | DONE (this file) | |
| research_status.md | PENDING (next) | |
| freshness.json | PENDING (next) | |

---

## Completeness Self-Assessment: ~65% (DECISION_DRAFT)

**What's strong**:
- Price independently verified against 2 sources, exact match to frozen input ($65.57)
- China geographic revenue split newly quantified this run (−15% YoY, 9.85% of total) — closes a major prior gap and directly serves the career-relevant thesis
- 3-year financial trend (FY23-25) plus most recent quarter (Q1 2026) both captured with segment-level detail
- 3-scenario IRR model built with explicit, documented assumptions and a clean methodology note
- 5-soul IC panel completed with genuine critique-round dynamics (not just 5 independent paragraphs) and zero fabricated quotes

**What's explicitly incomplete** (see facts.md OPEN O1-O9 for full detail):
- O1: Direct SEC 10-K/10-Q text never read (403 blocked both attempts, per-rule no retry) — relied on A2-proxy structured mirrors, cross-checked but not primary-verbatim
- O2: Clean adj EBITDA/D&A not disclosed anywhere found — valuation multiples use an estimated D&A add-back (~3.5% of revenue), explicitly flagged as an approximation, not a confirmed figure
- O4: Patient Care Solutions −8.1% organic decline root cause unconfirmed — the single most important unresolved OPERATING question
- O7: AI-attributable revenue/attach-rate/ASP premium completely unquantified — the single most important unresolved STRATEGIC question, and the one most relevant to the career thesis
- O8: No earnings call transcript fetched this run (time/efficiency tradeoff, consistent with DECISION_DRAFT-not-perfection target) — would likely resolve O4 and provide qualitative color on O7

**Ceiling determination**: This dossier is capped at DECISION_DRAFT, not COMPLETE, primarily due to O2/O4/O7/O8. This is consistent with the RUNNER's explicit instruction ("DECISION_DRAFT ~65% is the target, not perfection") — the checker confirms the run hit its target completeness band without over- or under-shooting.

---

## Verdict

**PASS — dossier meets the DECISION_DRAFT standard set by the RUNNER instructions.** All required files present, internally consistent (per audit.md), with explicit, honest OPEN-item registration rather than false completeness. Recommended next-refresh priorities, in order: (1) Q1 2026 earnings call transcript (resolves O4, partially informs O7), (2) direct 10-K MD&A/footnote read if SEC access improves (resolves O1, O2), (3) any subsequent GEHC disclosure on AI-product revenue attribution (resolves O7).
